News

The blinded, ascending, single dose study demonstrated that RG3039 was well tolerated at all doses administered and showed evidence of a dose-related drug response resulting in 90% inhibition

The study showed that levomilnacipran considerably reduced depression symptoms in MDD patients compared to placebo and further analyses of the data are ongoing. The companies expect to file

Hi-Tech is in the process of launching Lidocaine 5% Ointment, indicated for use as a local anesthetic, and the profits from the sale of the product will be

Alogliptin is a DPP-4 inhibitor that is being investigated in the US, as an adjunct to diet and exercise, for the treatment of type 2 diabetes. The FDA

The open-label Phase II clinical trial will evaluate the preliminary efficacy and safety of INNO-206 in pancreatic cancer. The patients enrolled in the trial will be treated with

In Phase III trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. Dynavax president and chief medical officer Tyler Martin said the final

Under the terms of the agreement, Teva may launch a generic epinephrine auto-injector covered by its ANDA on 22 June 2015 or earlier under certain circumstances, subject to

The approval is based on the results of the randomized, double-blind, placebo controlled Phase III study called PAzopanib ExpLorEd in sofT Tissue sarcoma (PALETTE). GSK Oncology president Paolo

The approval was based on the Phase III EXamining everolimus In a Study of TSC trial, which found that 42% of patients on everolimus experienced an angiomyolipoma response